Ignite Creation Date:
2025-12-24 @ 10:51 PM
Ignite Modification Date:
2026-05-17 @ 2:06 PM
Study NCT ID:
NCT01445769
Status:
COMPLETED
Last Update Posted:
2019-03-27
First Post:
2011-09-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Sponsor:
Incyte Corporation
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Post-Essential Thrombocythemia Myelofibrosis | View |
| None | PET-MF | View |
| None | Open label | View |
| None | Ruxolitinib | View |
| None | 18424 | View |
| None | Jak inhibitor | View |
| None | Myelofibrosis | View |
| None | Primary Myelofibrosis | View |
| None | PMF | View |
| None | Post-Polycythemia Vera Myelofibrosis | View |
| None | PPV-MF | View |